Activity Dates: 03/07/2018-09/07/2018This recertification course is closed. Check the availability of the latest recertification products.
This self-study activity serves as an educational tool for pharmacists seeking Board Certified Psychiatric Pharmacist (BCPP) Recertification credit and other pharmacists and healthcare providers seeking advanced education in patient management, disease state management, information management, and health policy and practice management in the field of psychiatric pharmacy.
The articles selected by CPNP Recertification Editorial Board for the Literature Analysis are based on a 7-year curriculum. This curriculum is developed using the Board of Pharmaceutical Specialties' Content Outline for the Psychiatric Pharmacy Specialty Certification Examination as a guideline. Since CPNP became the sole BCPP Recertification provider in 2008, the articles are chosen to cover the three content domains - Domain I: Patient Management, Domain 2: Information Management, Domain 3: Health Policy and Practice Management.
The Literature Analysis is a self-study, online only, application-based continuing pharmacy education (CPE) activity that releases March 7, 2018. An application-based CPE activity requires that participants apply the information learned. The examination for this product often features case studies requiring that the participant apply the principles learned through the readings. The Literature Analysis includes:
To satisfactorily complete the Literature Analysis and receive 10 hours of BCPP Recertification and ACPE credit, candidates must meet the following requirements:
You will proceed through the following steps to satisfactorily complete this course:
Your ACPE credit will be submitted directly to CPE Monitor within 48 hours after the official exam review and minimum passing score determination (4 weeks after close date) as long as you have provided the relevant information in your profile. BCPP Recertification credit is earned and reported within the year the assessment is successfully completed.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 7 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
|Article Number||Topic||Article and Learning Objectives|
Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407- 411. DOI: 10.1111/ijcp.12142. PubMed PMID: 23574101.
Vázquez GH, Holtzman JN, Tondo L, Baldessarini RJ. Efficacy and tolerability of treatments for bipolar depression. J Affect Disord. 2015;183:258-62. DOI: 10.1016/j.jad.2015.05.016. PubMed PMID: 26042634.
Education Methods for Patients and the Public
Werremeyer A, Skoy E, Aalgaard Kelly G. Medication Experience of Psychotropic Medications through Photovoice. Qualitative Health Research. Published online March 1, 2017.
Texas Department of Family and Protective Services, The University of Texas at Austin College of Pharmacy. Psychotropic Medication Utilization Parameters for Children and Youth in Foster Care 5th Version. [Online]. 2016 Jul [cited 2017 Jul 18]; Available from: URL: http://www.dfps.state.tx.us/Child_Protection/Medical_Services/documents/reports/2016-03_Psychotropic_Medication_Utilization_Parameters_for_Foster_Children.pdf
Myers K, Stoep AV, Zhou C, McCarty CA, Katon W. Effectiveness of a telehealth service delivery model for treating attention-deficit/hyperactivity disorder: a community-based randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2015;54(4):263-74. DOI: 10.1016/j.jaac.2015.01.009. PubMed PMID: 25791143.
Haney M, Ramesh D, Glass A, Pavlicova M, Bedi G, Cooper ZD. Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers. Neuropsychopharmacology. 2015;40(11):2489-98. DOI: 10.1038/npp.2015.108. PubMed PMID: 25881117.
Cooper SJ, Reynolds GP, Barnes TRE, England E, Haddad PM, Heald A, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016;30(8):717-48. DOI: 10.1177/0269881116645254. PubMed PMID: 27147592.
Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507-20. DOI: 10.1016/S0140-6736(16)30272-0. PubMed PMID: 27116918.
The Recertification Editorial Board generally avoids using industry-sponsored trials for our literature analysis product. In this case, this study was FDA-mandated and the investigators received other funding from non-industry sources. In addition, the findings from this study are both scientifically and clinically important.
Traumatic Brain Injury
Ponsford J, Lee NK, Wong D, McKay A, Haines K, Alway Y, et al. Efficacy of motivational interviewing and cognitive behavioral therapy for anxiety and depression symptoms following traumatic brain injury. Psychol. Med. 2016;46(05):1079- 1090. DOI: 10.1017/S0033291715002640. PubMed PMID: 26708017.
Treatment Resistant Depression
Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(10011):2404- 2412. DOI: 10.1016/S0140-6736(15)00308-6.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Literature Analysis product is an application-based program approved for 10 hours of ACPE credit. To receive ACPE credit, pharmacists completing this programming are required to complete an evaluation of the course as well as pass an online examination. BCPP Recertification credit is earned and reported within the year the assessment is successfully completed.
Board Certified Psychiatric Pharmacists (BCPPs) may also receive 10 hours of BCPP Recertification Credit for the Literature Analysis upon successful completion of an online examination.
CPNP will report credits earned into CPE Monitor within 48 hours after successful exam completion. Recertification credit will be reported after official exam review and cut-off score determination occurs (within 4 weeks of close date for course). ACPE transcripts reflecting CPE Monitor reporting are available at cpnp.org/mycpnp/transcript/acpe. You can access your BCPP Recertification transcript at cpnp.org/bcpp/transcript. This user-friendly transcript provides real-time access to a listing of the BCPP Recertification programming you have successfully completed in your current 7-year cycle along with your BCPP number and links to other BCPP Recertification resources.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
It is the policy of CPNP to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.
Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse effects, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions before dispensing or administering the drug or using the drug delivery system.
Fair balance is achieved through ongoing and thorough review of all materials produced before educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CPNP for any product or manufacturer identified.
In accordance with the Food and Drug Administration (FDA), it is disclosed that there is the potential for discussions concerning off-label uses of a commercial product/devices during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in this activity. Significant relationships include receiving research grants, consultant fees, travel, other benefits from a commercial company, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
CPNP planners and managers have no relationships to disclose related to the content of this CE activity.